NCT02981108 - A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | Biotech Hunter

Enrollment

364

Participants

Timeline

Start Date

May 8, 2017

Primary Completion Date

January 5, 2019

Study Completion Date

March 31, 2023

Conditions

Nonsmall Cell Lung Cancer

Interventions

DRUG

HS-10296

HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Trial Locations (10)

30607

University Cancer & Blood Center, LLC, Athens

33442

Sylvester Comprehensive Cancer Center, Deerfield Beach

47150

Baptist Healthcare Systems Inc. Baptist Health Floyd, New Albany

77550

University of Texas Medical Branch at Galveston, Galveston

80045

University of Colorado-1775 Aurora Court, Aurora

90211

Beverly Hills Cancer Center, Beverly Hills

92093

University of California San Diego Medical Center Moores Cancer Center, San Diego

92801

Pacific Cancer Medical Center, Inc., Anaheim

98405

MultiCare Institute for Research and Innovation, Tacoma

03755

Dartmouth-Hitchcock Medical Center, Hanover